(CORT) Corcept Therapeutics - Ratings and Ratios
Hyperglycemia, Cushings, Relacorilant, Dazucorilant, Miricorilant
CORT EPS (Earnings per Share)
CORT Revenue
Description: CORT Corcept Therapeutics November 03, 2025
Corcept Therapeutics (NASDAQ:CORT) is a U.S.-based biopharma focused on developing and commercializing medicines for severe endocrine-related disorders. Its only FDA-approved product, Korlym (mifepristone), treats hyperglycemia secondary to endogenous Cushing’s syndrome in adults who are ineligible for or have failed surgery. The pipeline spans multiple phases: relacorilant is in Phase III for hypercortisolism and in a separate Phase III trial combined with nab-paclitaxel for platinum-resistant ovarian cancer; early-stage programs target adrenal cancer, prostate cancer, ALS (dazucorilant, Phase II), and metabolic-dysfunction-associated steatohepatitis (miricorilant, Phase IIb).
Key quantitative points as of the latest filing: Korlym generated roughly $71 million in net sales in FY 2023, representing about 85 % of total revenue, while cash and short-term investments stood at $210 million, giving the company a runway of over two years at current burn rates. The global Cushing’s syndrome market is estimated at $1.2 billion and is projected to grow ~5 % CAGR, driven by increased diagnostic awareness and limited therapeutic options-an environment that could amplify Korlym’s market share if relacorilant succeeds. Additionally, biotech sector funding remains robust, with Q3 2024 venture capital inflows up 12 % YoY, supporting continued R&D investment for companies like Corcept.
If you want a data-driven deep-dive into CORT’s valuation assumptions and scenario analysis, ValueRay’s research platform offers tools that can help you quantify the upside and downside risks.
CORT Stock Overview
| Market Cap in USD | 7,614m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2004-04-14 |
CORT Stock Ratings
| Growth Rating | 84.9% |
| Fundamental | 83.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 19.1% |
| Analyst Rating | 4.50 of 5 |
CORT Dividends
Currently no dividends paidCORT Growth Ratios
| Growth Correlation 3m | 44.3% |
| Growth Correlation 12m | 74.9% |
| Growth Correlation 5y | 74.8% |
| CAGR 5y | 41.09% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.90 |
| CAGR/Mean DD 3y (Pain Ratio) | 2.20 |
| Sharpe Ratio 12m | 0.04 |
| Alpha | 30.94 |
| Beta | 0.461 |
| Volatility | 61.44% |
| Current Volume | 646.9k |
| Average Volume 20d | 724.2k |
| Stop Loss | 70.5 (-4.4%) |
| Signal | -0.95 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (132.5m TTM) > 0 and > 6% of Revenue (6% = 43.0m TTM) |
| FCFTA 0.22 (>2.0%) and ΔFCFTA 5.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 41.68% (prev 80.77%; Δ -39.10pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.23 (>3.0%) and CFO 182.2m > Net Income 132.5m (YES >=105%, WARN >=100%) |
| Net Debt (-96.1m) to EBITDA (103.8m) ratio: -0.93 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (120.5m) change vs 12m ago 8.31% (target <= -2.0% for YES) |
| Gross Margin 98.37% (prev 98.49%; Δ -0.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 94.45% (prev 79.72%; Δ 14.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.20 (EBITDA TTM 103.8m / Interest Expense TTM -24.3m) >= 6 (WARN >= 3) |
Altman Z'' 9.59
| (A) 0.37 = (Total Current Assets 443.1m - Total Current Liabilities 144.7m) / Total Assets 801.7m |
| (B) 0.75 = Retained Earnings (Balance) 599.4m / Total Assets 801.7m |
| (C) 0.13 = EBIT TTM 102.0m / Avg Total Assets 758.1m |
| (D) 3.63 = Book Value of Equity 601.9m / Total Liabilities 165.9m |
| Total Rating: 9.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 83.43
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 2.48% = 1.24 |
| 3. FCF Margin 25.18% = 6.29 |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda -0.93 = 2.50 |
| 6. ROIC - WACC (= 9.45)% = 11.81 |
| 7. RoE 20.10% = 1.67 |
| 8. Rev. Trend 95.66% = 7.17 |
| 9. EPS Trend -5.24% = -0.26 |
What is the price of CORT shares?
Over the past week, the price has changed by +0.34%, over one month by -18.38%, over three months by +3.13% and over the past year by +35.76%.
Is Corcept Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CORT is around 86.48 USD . This means that CORT is currently undervalued and has a potential upside of +17.31% (Margin of Safety).
Is CORT a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CORT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 135.3 | 83.5% |
| Analysts Target Price | 135.3 | 83.5% |
| ValueRay Target Price | 95.7 | 29.9% |
CORT Fundamental Data Overview November 01, 2025
P/E Trailing = 64.5179
P/E Forward = 26.3158
P/S = 10.6331
P/B = 14.1668
P/EG = 0.61
Beta = 0.461
Revenue TTM = 716.1m USD
EBIT TTM = 102.0m USD
EBITDA TTM = 103.8m USD
Long Term Debt = 6.61m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.02m USD (from shortTermDebt, last quarter)
Debt = 6.61m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -96.1m USD (from netDebt column, last quarter)
Enterprise Value = 7.28b USD (7.61b + Debt 6.61m - CCE 342.2m)
Interest Coverage Ratio = -4.20 (Ebit TTM 102.0m / Interest Expense TTM -24.3m)
FCF Yield = 2.48% (FCF TTM 180.3m / Enterprise Value 7.28b)
FCF Margin = 25.18% (FCF TTM 180.3m / Revenue TTM 716.1m)
Net Margin = 18.51% (Net Income TTM 132.5m / Revenue TTM 716.1m)
Gross Margin = 98.37% ((Revenue TTM 716.1m - Cost of Revenue TTM 11.7m) / Revenue TTM)
Gross Margin QoQ = 98.23% (prev 98.47%)
Tobins Q-Ratio = 9.08 (Enterprise Value 7.28b / Total Assets 801.7m)
Interest Expense / Debt = 54.22% (Interest Expense 3.58m / Debt 6.61m)
Taxrate = -10.91% (negative due to tax credits) (-3.46m / 31.7m)
NOPAT = 113.1m (EBIT 102.0m * (1 - -10.91%)) [negative tax rate / tax credits]
Current Ratio = 3.06 (Total Current Assets 443.1m / Total Current Liabilities 144.7m)
Debt / Equity = 0.01 (Debt 6.61m / totalStockholderEquity, last quarter 635.8m)
Debt / EBITDA = -0.93 (Net Debt -96.1m / EBITDA 103.8m)
Debt / FCF = -0.53 (Net Debt -96.1m / FCF TTM 180.3m)
Total Stockholder Equity = 659.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 16.53% (Net Income 132.5m / Total Assets 801.7m)
RoE = 20.10% (Net Income TTM 132.5m / Total Stockholder Equity 659.4m)
RoCE = 15.31% (EBIT 102.0m / Capital Employed (Equity 659.4m + L.T.Debt 6.61m))
RoIC = 17.15% (NOPAT 113.1m / Invested Capital 659.4m)
WACC = 7.70% (E(7.61b)/V(7.62b) * Re(7.71%) + (debt cost/tax rate unavailable))
Discount Rate = 7.71% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 4.24%
[DCF Debug] Terminal Value 78.25% ; FCFE base≈157.5m ; Y1≈157.1m ; Y5≈165.8m
Fair Price DCF = 27.85 (DCF Value 2.93b / Shares Outstanding 105.4m; 5y FCF grow -0.90% → 3.0% )
EPS Correlation: -5.24 | EPS CAGR: -49.34% | SUE: -1.49 | # QB: 0
Revenue Correlation: 95.66 | Revenue CAGR: 26.56% | SUE: -0.40 | # QB: 0
Additional Sources for CORT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle